Mucosal vaccines and technology

Miquel-Clopés, Ariadna; Bentley, Eleanor G.; Stewart, James P.; Carding, Simon R.

doi:10.1111/cei.13285

Cited by 120 publications

(134 citation statements)

References 82 publications

(97 reference statements)

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…The interactions of L. monocytogenes with M cells have also been succinctly characterized and remain poorly understood. Currently there are no vaccines available against S. flexneri, L. monocytogenes and many other mucosal-transmitted infectious diseases initiated through M cells [16]. Thus there is a pressing need to elaborate experimental workflows allowing to finely characterize M cell host-pathogen interactions.…”

Section: Introductionmentioning

confidence: 99%

Transcytosis subversion by M cell-to-enterocyte spread promotes Shigella flexneri and Listeria monocytogenes intracellular bacterial dissemination

et al. 2020

View full text Add to dashboard Cite

Microfold (M) cell host-pathogen interaction studies would benefit from the visual analysis of dynamic cellular and microbial interplays. We adapted a human in vitro M cell model to physiological bacterial infections, expression of fluorescent localization reporters and long-term three-dimensional time-lapse microscopy. This approach allows following key steps of M cell infection dynamics at subcellular resolution, from the apical onset to basolateral epithelial dissemination. We focused on the intracellular pathogen Shigella flexneri, classically reported to transcytose through M cells to initiate bacillary dysentery in humans, while eliciting poorly protective immune responses. Our workflow was critical to reveal that S. flexneri develops a bimodal lifestyle within M cells leading to rapid transcytosis or delayed vacuolar rupture, followed by direct actin motility-based propagation to neighboring enterocytes. Moreover, we show that Listeria monocytogenes, another intracellular pathogen sharing a tropism for M cells, disseminates in a similar manner and evades M cell transcytosis completely. We established that actin-based M cell-to-enterocyte spread is the major dissemination pathway for both pathogens and avoids their exposure to basolateral compartments in our system. Our results challenge the notion that intracellular pathogens are readily transcytosed by M cells to inductive immune compartments in vivo, providing a potential mechanism for their ability to evade adaptive immunity.

show abstract

Section: Introductionmentioning

confidence: 99%

Transcytosis subversion by M cell-to-enterocyte spread promotes Shigella flexneri and Listeria monocytogenes intracellular bacterial dissemination

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Critical alternatives for the development of mucosal vaccines include guaranteeing antigen delivery and immunostimulating capacity at the mucosa, while at the same time being minimally reactogenic/toxic. Among the immunopotentiator molecules that can be explored are bacterial toxin derivatives, toll-like receptor ligands, and cytokines [102,103].…”

Section: Relevance Of Mucosal Vaccines and Prime-boosting Immunizatiomentioning

confidence: 99%

What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?

et al. 2020

View full text Add to dashboard Cite

The emergence of new pathogenic viral strains is a constant threat to global health, with the new coronavirus strain COVID-19 as the latest example. COVID-19, caused by the SARS-CoV-2 virus has quickly spread around the globe. This pandemic demands rapid development of drugs and vaccines. Plant-based vaccines are a technology with proven viability, which have led to promising results for candidates evaluated at the clinical level, meaning this technology could contribute towards the fight against COVID-19. Herein, a perspective in how plant-based vaccines can be developed against COVID-19 is presented. Injectable vaccines could be generated by using transient expression systems, which offer the highest protein yields and are already adopted at the industrial level to produce VLPs-vaccines and other biopharmaceuticals under GMPC-processes. Stably-transformed plants are another option, but this approach requires more time for the development of antigen-producing lines. Nonetheless, this approach offers the possibility of developing oral vaccines in which the plant cell could act as the antigen delivery agent. Therefore, this is the most attractive approach in terms of cost, easy delivery, and mucosal immunity induction. The development of multiepitope, rationally-designed vaccines is also discussed regarding the experience gained in expression of chimeric immunogenic proteins in plant systems.

show abstract

“…Reports estimate that 70-90% of pathogens of concern in human and veterinary medicine invade mucosal surfaces, either to cause a local infection or to disseminate and provoke systemic diseases. [1][2][3][4] As this seems to be an underappreciated fact, a primary focus of vaccinology has been to develop immunogens intended to be inoculated parenterally, and to evaluate immune responses only in serum, failing to elicit optimal protection at mucosal membranes. [5][6][7] This situation highlights an urgent and still unmet goal to develop vaccines and immu-Abbreviations: AcMNPV, Autographa californica multiple nucleopolyhedrovirus; cDCs, conventional or classical dendritic cells; CpG-ODNs, unmethylated cytosine-guanine-containing oligonucleotides; FAE, follicle-associated epithelium; GP64, major envelope glycoprotein from AcMNPV; HPV, human papillomavirus; LNs, lymph nodes;…”

Section: Introductionmentioning

confidence: 99%

Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations

Fragoso-Saavedra

Vega-Lopez

2020

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Over 90% of pathogens of medical importance invade the organism through mucosal surfaces, which makes it urgent to develop safe and effective mucosal vaccines and mucosal immunization protocols. Besides, parenteral immunization does not provide adequate protective immunity in mucosal surfaces. Effective mucosal vaccination could protect local and systemic compartments and favor herd immunity. Although various mucosal adjuvants and Ag‐delivery systems have been developed, none has filled the gap to control diseases caused by complex mucosal pathogens. Among the strategies to counteract them, recombinant virions from the baculovirus Autographa californica multiple nucleopolyhedrovirus (rAcMNPV) are useful vectors, given their safety and efficacy to produce mucosal and systemic immunity in animal infection models. Here, we review the immunogenic properties of rAcMNPV virions from the perspectives of mucosal immunology and vaccinology. Some features, which are analyzed and extrapolated from studies with different particulate antigens, include size, shape, surface molecule organization, and danger signals, all needed to break the tolerogenic responses of the mucosal immune tissues. Also, we present a condensed discussion on the immunity provided by rAcMNPV virions against influenza virus and human papillomavirus in animal models. Through the text, we highlight the advantages and limitations of this experimental immunization platform.

show abstract

Mucosal vaccines and technology

Cited by 120 publications

References 82 publications

Transcytosis subversion by M cell-to-enterocyte spread promotes Shigella flexneri and Listeria monocytogenes intracellular bacterial dissemination

Transcytosis subversion by M cell-to-enterocyte spread promotes Shigella flexneri and Listeria monocytogenes intracellular bacterial dissemination

What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?

Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations

Contact Info

Product

Resources

About